Clinical Commander

Back to dossier
cardio.hypertensive-emergency.acute-pulmonary-edema.v1PRODUCTION
cardio.hypertensive-emergency.acute-pulmonary-edema.v1

Hypertensive emergency with acute (flash) pulmonary edema

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Flash pulmonary edema with HTN — preload + afterload reduction FIRST (IV nitroglycerin); IV loop diuretic; NIPPV reduces intubation rate (3CPO PMID 18768944). Goal SBP ↓ 25% in first hour. Inherits HTN-emergency framework from parent. ACS overlap requires cath lab activation.

Inputs
4
Actions
0
Advance rule
Set
Advance when

flash pulm edema phenotype confirmed

Patient inputs (12)

Older patients more likely to have HFpEF + flash edema phenotype (PAGE-PE PMID 33872318)

Orthopnea + PND classic for cardiogenic pulm edema vs ARDS or PNA

AKI co-presence drives diuretic dose + nitroprusside avoidance; cardiorenal syndrome common

ACS overlap possible — flash pulm edema may herald MI (route to cardio.stemi/nstemi if positive)

Bilateral infiltrates + cephalization + Kerley B lines confirm cardiogenic edema vs ARDS

Rule out STEMI overlap (route to cath if ST↑); LVH typical in chronic HTN

EF + valvular (acute MR/AS) + diastolic function (HFpEF vs HFrEF) → drives chronic GDMT path

O2 + NIPPV titration; SpO2 <90 RA on presentation typical

RR >25-30 + accessory muscle use → NIPPV; RR >35 + AMS → consider intubation

Goal SBP ↓ 25% in first hour; preserve perfusion (ACC/AHA 2025)

BNP >500 LR+ 8.1 for AHF (Maisel NEJM 2002 PMID 12124404); confirms cardiogenic etiology

POCUS B-lines highly sensitive (LR+ 13 per BLUE protocol PMID 18403664) + bedside available

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (5)

5 need judgement
  • informationallife_threateningrefractory_hypoxemia_intubation
    SpO2 <85 on NIPPV with FiO2 100% OR worsening RR/AMS despite NIPPV — failure of non-invasive support
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningacs_overlap_in_flash_edema
    Positive troponin or dynamic ST changes in flash pulmonary edema — ACS-driven flash edema (often anterior STEMI with acute LV failure)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningcardiogenic_shock_in_flash_edema
    Flash pulm edema + SBP <90 + lactate ≥2 + organ hypoperfusion — SCAI C+ cardiogenic shock
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningacute_valvular_emergency_in_flash_edema
    New severe MR or AR (papillary rupture, endocarditis, dissection-related AI) presenting as flash pulm edema
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecardiorenal_syndrome_with_rising_creatinine
    Rising Cr (>30% from baseline) during diuresis OR persistent edema + AKI — cardiorenal syndrome
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

Flash pulm edema + HTN — preload + afterload reduction FIRST (IV NTG) + IV loop diuretic + NIPPV; goal SBP ↓ 25% in first hour
axis: flash_pulmonary_edema_preload_afterload_reduction
Selected axis "Flash pulm edema + HTN — preload + afterload reduction FIRST (IV NTG) + IV loop diuretic + NIPPV; goal SBP ↓ 25% in first hour" by default fallback (first axis)
  • nitroglycerin
    first line
    organic_nitrate
    5-10 µg/min IV, titrate by 5 µg/min q5min up to 200 µg/min • IV • continuous
    triggers: flash_pulmonary_edema, HTN_emergency_with_HF
    ACC/AHA 2025 first-line — preload + afterload reduction; rapid onset; PAGE-PE supports early titration (PMID 33872318); AVOID if SBP <90 / RV infarct / PDE5 within 24-48h
    rxcui 4917
  • furosemide
    first line
    loop_diuretic
    40-80 mg IV bolus (or 1-2× home daily dose if chronic HF) per DOSE PMID 21366472 • IV • q12h or continuous infusion 5-20 mg/h
    triggers: flash_pulmonary_edema_with_volume_overload
    DOSE trial (Felker NEJM 2011 PMID 21366472) — high-dose IV + bolus or continuous; reassess UOP at 2 h; titrate to net negative balance
    rxcui 4603
  • nicardipine
    second line
    DHP_CCB
    5 mg/h IV titrate by 2.5 mg/h q5-15 min • IV • continuous
    triggers: flash_pulm_edema_BP_control_after_nitrate_max, nitrate_intolerant
    Add when NTG alone insufficient or contraindicated; safe with HF (does not worsen LV function)
    rxcui 7396
  • nitroprusside
    second line
    arteriolar_venodilator
    0.25-10 µg/kg/min IV titrate • IV • continuous
    triggers: flash_pulm_edema_refractory_after_NTG_max, normal_egfr_no_coronary_disease
    Rapid afterload reduction; AVOID if eGFR <30 (cyanide) OR coronary ischemia (coronary steal); ACC/AHA 2025 acceptable adjunct
    rxcui 7476
  • labetalol
    comorbidity specific
    mixed_alpha_beta_blocker
    20 mg IV q10 min • IV • bolus
    triggers: flash_pulm_edema_with_tachycardia_and_no_acute_HF_decompensation
    Cautious use — BB in acute decompensated HF can worsen — only if tachycardia + EF preserved + responding to NTG/diuretic
    rxcui 6185
  • NIPPV (CPAP 8-10 cmH2O or BiPAP 12/5)
    first line
    non_invasive_ventilation
    CPAP 8-10 cmH2O OR BiPAP IPAP 12 / EPAP 5; titrate to SpO2 >92 • mask • continuous
    triggers: flash_pulm_edema_with_respiratory_distress
    3CPO trial (Gray NEJM 2008 PMID 18768944) — NIPPV reduces intubation rate vs standard O2 in cardiogenic pulm edema; equivalent CPAP vs BiPAP
  • AVOID isolated diuretic without vasodilator
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: flash_pulm_edema_with_severe_HTN
    Diuretic alone without afterload reduction in HTN-driven flash edema is incomplete unloading — preload + afterload reduction with NTG is the FIRST move (ACC/AHA 2025; ESC 2021 HF PMID 34447992)

outpatient playbook — drug actions (1)

  1. 1. continue 4-tier oral + GDMT
    rxcui 17767
    Per maintenance regimen • PO • as scheduled
    trigger: Stable maintenance
    ACC/AHA 2025 + ACC/AHA 2022 HF

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: SBP >180 + acute respiratory distress + bilateral B-lines / pulmonary edema on CXR (ACC/AHA 2025; Vaughan Lancet 2000 PMID 10972386); Acute dyspnea + orthopnea + pink frothy sputum (classic flash pulm edema); Lung US with diffuse B-lines (LR+ 13 per Lichtenstein BLUE protocol PMID 18403664).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Hypertensive emergency with acute (flash) pulmonary edema** (cardio.hypertensive-emergency.acute-pulmonary-edema.v1).
Scope: Flash pulmonary edema with HTN — preload + afterload reduction FIRST (IV nitroglycerin); IV loop diuretic; NIPPV reduces intubation rate (3CPO PMID 18768944). Goal SBP ↓ 25% in first hour. Inherits HTN-emergency framework from parent. ACS overlap requires cath lab activation.

No severity triggers fired against current inputs.

Plan

Regimen axis: **Flash pulm edema + HTN — preload + afterload reduction FIRST (IV NTG) + IV loop diuretic + NIPPV; goal SBP ↓ 25% in first hour**.
1. nitroglycerin 5-10 µg/min IV, titrate by 5 µg/min q5min up to 200 µg/min IV continuous (organic_nitrate, first line) — ACC/AHA 2025 first-line — preload + afterload reduction; rapid onset; PAGE-PE supports early titration (PMID 33872318); AVOID if SBP <90 / RV infarct / PDE5 within 24-48h
2. furosemide 40-80 mg IV bolus (or 1-2× home daily dose if chronic HF) per DOSE PMID 21366472 IV q12h or continuous infusion 5-20 mg/h (loop_diuretic, first line) — DOSE trial (Felker NEJM 2011 PMID 21366472) — high-dose IV + bolus or continuous; reassess UOP at 2 h; titrate to net negative balance
3. nicardipine 5 mg/h IV titrate by 2.5 mg/h q5-15 min IV continuous (DHP_CCB, second line) — Add when NTG alone insufficient or contraindicated; safe with HF (does not worsen LV function)
4. nitroprusside 0.25-10 µg/kg/min IV titrate IV continuous (arteriolar_venodilator, second line) — Rapid afterload reduction; AVOID if eGFR <30 (cyanide) OR coronary ischemia (coronary steal); ACC/AHA 2025 acceptable adjunct
5. labetalol 20 mg IV q10 min IV bolus (mixed_alpha_beta_blocker, comorbidity specific) — Cautious use — BB in acute decompensated HF can worsen — only if tachycardia + EF preserved + responding to NTG/diuretic
6. NIPPV (CPAP 8-10 cmH2O or BiPAP 12/5) CPAP 8-10 cmH2O OR BiPAP IPAP 12 / EPAP 5; titrate to SpO2 >92 mask continuous (non_invasive_ventilation, first line) — 3CPO trial (Gray NEJM 2008 PMID 18768944) — NIPPV reduces intubation rate vs standard O2 in cardiogenic pulm edema; equivalent CPAP vs BiPAP
7. AVOID isolated diuretic without vasodilator AVOID N/A N/A (do_not_use, contraindication substitute) — Diuretic alone without afterload reduction in HTN-driven flash edema is incomplete unloading — preload + afterload reduction with NTG is the FIRST move (ACC/AHA 2025; ESC 2021 HF PMID 34447992)

Setting playbook (outpatient) — Long-term cardiology surveillance — secondary prevention, GDMT maintenance, BP <130/80, weight stability, recurrence prevention
8. continue 4-tier oral + GDMT Per maintenance regimen PO as scheduled — Stable maintenance (ACC/AHA 2025 + ACC/AHA 2022 HF)

Non-pharmacologic actions:
- Sodium + fluid restriction maintenance
- Cardiac rehab maintenance phase
- Annual flu + COVID + pneumococcal vaccinations

AVOID / contraindication checks:
- NTG_avoid_sbp_lt_90 (ACC/AHA 2025)
- NTG_avoid_rv_infarct (ACC/AHA 2025)
- NTG_avoid_pde5_within_24 48h (ACC/AHA 2025)
- Nitroprusside_avoid_egfr_lt_30_cyanide (ACC/AHA 2025)
- Nitroprusside_avoid_coronary_ischemia_steal (ACC/AHA 2025)
- Isolated_diuretic_avoid_in_HTN_flash_edema_incomplete_unloading (ACC/AHA 2025)
- BB_caution_in_acute_decompensated_HF (ESC 2021 HF)

Monitoring

Regimen monitoring:
- arterial line q5-15min BP (ACC/AHA 2025)
- continuous SpO2 target gt 92 (ESC 2021 HF)
- hourly UOP (ACC/AHA 2025)
- serial troponin q6h x 3 to rule out ACS (ACC/AHA 2025; ACC/AHA 2023 Chest Pain)
- serial BMP q6h for K Cr (DOSE PMID 21366472)
- daily weight and strict I O (ESC 2021 HF)
- echo at 24-48h for EF and valvular reassessment (ESC 2021 HF)

Setting (outpatient) monitoring:
- Quarterly BP + weight
- Annual echo

Follow-up plan: Transition to oral 4-tier ladder + GDMT if HFrEF; secondary cause workup (RAS, OSA, dietary indiscretion, medication non-adherence); 1-week follow-up; cardiac rehab if first HF episode
- Close-out criterion: oral regimen stable + 1-wk follow-up booked

Monitoring phase: Arterial line + q5-15 min BP; continuous SpO2 + ECG; hourly UOP; serial troponin q6h × 3 (rule out ACS); BMP q6h; daily weight + I/O; echo at 24-48 h for EF + valvular reassessment

Disposition

Current setting: outpatient — Long-term cardiology surveillance — secondary prevention, GDMT maintenance, BP <130/80, weight stability, recurrence prevention

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + cardio.hfref.core.v1 (or hfpef)

Escalation triggers (move to higher acuity):
- Weight gain trigger → clinic
- Symptom recurrence → reassessment

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] SpO2 <85 on NIPPV with FiO2 100% OR worsening RR/AMS despite NIPPV — failure of non-invasive support
- [LIFE_THREATENING] Positive troponin or dynamic ST changes in flash pulmonary edema — ACS-driven flash edema (often anterior STEMI with acute LV failure)
- [LIFE_THREATENING] Flash pulm edema + SBP <90 + lactate ≥2 + organ hypoperfusion — SCAI C+ cardiogenic shock

Citations

- 2025 ACC/AHA HTN Guideline (Whelton) + ESC 2021 HF Guideline (PMID 34447992) + 3CPO (PMID 18768944) + DOSE (PMID 21366472) [PMID:38316810](https://pubmed.ncbi.nlm.nih.gov/38316810/)
- Cited evidence (PMID 38613493) [PMID:38613493](https://pubmed.ncbi.nlm.nih.gov/38613493/)
- Cited evidence (PMID 34447992) [PMID:34447992](https://pubmed.ncbi.nlm.nih.gov/34447992/)
- Cited evidence (PMID 18768944) [PMID:18768944](https://pubmed.ncbi.nlm.nih.gov/18768944/)
- Cited evidence (PMID 21366472) [PMID:21366472](https://pubmed.ncbi.nlm.nih.gov/21366472/)

Last reconciled with current guidelines: 2026-05-14.
References
  • 2025 ACC/AHA HTN Guideline (Whelton) + ESC 2021 HF Guideline (PMID 34447992) + 3CPO (PMID 18768944) + DOSE (PMID 21366472) — PMID:38316810
  • Cited evidence (PMID 38613493) — PMID:38613493
  • Cited evidence (PMID 34447992) — PMID:34447992
  • Cited evidence (PMID 18768944) — PMID:18768944
  • Cited evidence (PMID 21366472) — PMID:21366472